Oral apremilast in the treatment of active psoriatic arthritis; Results of a multicenter, randomized, double-blind, placebo-controlled study

Arthritis and Rheumatism

Volumn 64, Issue 10, 2012, Pages 3156-3167

  Schett, Georg ^a   Wollenhaupt, Jurgen ^b   Papp, Kim ^c   Joos, Rik ^d   Rodrigues, Jude F ^e   Vessey, Adele R ^f   Hu, Chiachi ^f   Stevens, Randall ^f   De Vlam, Kurt L ^g  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Klinikum Eilbek   (Germany)

^c PROBITY MEDICAL RESEARCH   (Canada)

^d ZiekenhuisNetwerk Antwerpen   (Belgium)

^e Clinical Research and Arthritis Centre   (Canada)

^f CELGENE CORPORATION   (United States)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; PLACEBO;

ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SORE THROAT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84869014252     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34627     Document Type: Article

References (33)

1. National Psoriasis Foundation. Report on the psycho-social impacts of psoriasis. 2009. URL: http://www.psoriasis.org/Net Community/Document.Doc?id- 619.
2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl II:ii14-17. (Pubitemid 40288513)
3. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-12. (Pubitemid 20213507)
4. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003; 42: 778-83. (Pubitemid 37220911)
5. Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmstrom G, Larsson PT, and the Psoriatic Arthritis Group of the Society for Rheumatology. The Swedish Early Psoriatic Arthritis register - 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008; 35: 668-73. (Pubitemid 351500064)
6. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72. (Pubitemid 38924405)
7. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89. (Pubitemid 41447111)
8. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor - antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study [published erratum appears in Arthritis Rheum 2010;62:2555]. Arthritis Rheum 2009; 60: 976-86.
9. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64: 1150-7. (Pubitemid 41113349)
10. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11: 180-210.
11. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebocontrolled, crossover trial. Lancet 2009; 373: 633-40.
12. Mease PJ, Gladman DD, Keystone EC, on behalf of the Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54: 1638-45.
13. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, doubleblind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63: 939-48.
14. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69 Suppl I:i2-29.
15. Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics 2008; 26: 121-9.
16. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying antirheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008; 67: 855-9. (Pubitemid 351829388)
17. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005; 64: 859-64. (Pubitemid 40733909)
18. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-59.
19. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69: 43-7.
20. Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010; 220: 128-37.
21. Pages L, Gavalda A, Lehner MD. PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin Ther Pat 2009; 19:1501-19.
22. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159: 842-55.
23. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase- 4 as a therapeutic target. Drug Discov Today 2005;10: 1503-19. (Pubitemid 41527193)
24. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
25. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
26. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
27. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007; 57: 193-202.
28. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996; 39: 2013-20.
29. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/ International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40. (Pubitemid 26036375)
30. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154-61. (Pubitemid 47057851)
31. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006;129: 56-66. (Pubitemid 43265243)
32. Van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005; 116: 292-8. (Pubitemid 41096533)
33. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomized controlled trial. Lancet 2012. E-pub ahead of print.